SCHEDULE: GoHealth Secures $115M Loan, Issues Equity, Reshapes Board

GoHealth, Inc. has secured a new $115 million superpriority term loan facility, issued new equity to lenders, and implemented significant board changes as part of a broader financial restructuring.

Summary

• GoHealth, Inc. (through its subsidiary Norvax, LLC) entered into a $115.0 million Superpriority Senior Secured Credit Agreement on August 6, 2025.
• The new facility comprises $80.0 million in new-money term loans ($40.0 million funded immediately, $40.0 million available as delayed-draw) and $35.0 million in roll-up term loans from converted existing Class A revolving loans.
• An amendment to the existing Credit Agreement extends the maturity of remaining Class A revolving loans to August 5, 2029.
• Interest on outstanding Existing Term Loans and Class A revolving loans will accrue at Adjusted Term SOFR plus 8.00% per annum, with at least 4.50% payable in cash and the remainder as pay-in-kind (PIK) interest.
• Amortization of Existing Term Loans is waived until December 31, 2026, and certain financial covenants (total cash leverage, asset coverage, budget variance) have been removed.
• As a condition of the financing, GoHealth issued 4,766,219 shares of Class A common stock to lenders, representing 19.99% of the total issued and outstanding Class A and Class B common stock immediately prior to the transaction.
• The Board of Directors appointed three new directors, and three existing directors (Alexander E. Timm, Alan Wheatley, and Karoline Hilu) resigned immediately before the closing of the transactions.
• A Transformation Committee was established, consisting of the new directors and Jeremy W. Gelber.
• Major shareholders, Centerbridge Parties and NVX Holdings, provided irrevocable consent and waivers of certain rights under their Stockholders Agreement and Registration Rights Agreement to facilitate these transactions.

Sentiment

Score: 3

Explanation: While the company secured financing, the terms (superpriority, high interest, PIK, significant equity dilution, loss of board control for existing shareholders, removal of covenants) strongly indicate severe financial distress and a last-resort measure. This is a 'rescue' package, not a sign of strength.

Positives

• Secured $115.0 million in new financing, providing crucial liquidity for operations.
• Extended the maturity date of remaining Class A revolving loans to August 5, 2029, improving the company's debt maturity profile.
• Waiver of existing term loan amortization until December 31, 2026, which will ease near-term cash flow demands.
• Removal of certain financial covenants (total cash leverage, asset coverage, budget variance) provides greater operational flexibility.
• Establishment of a Transformation Committee suggests a focused effort on strategic improvements and a potential turnaround.

Negatives

• Issuance of 4,766,219 new Class A shares to lenders results in significant dilution of 19.99% for existing shareholders.
• The high interest rate on existing term loans and Class A revolving loans (Adjusted Term SOFR + 8.00%), with a portion payable in kind, indicates financial distress and will increase future interest expense.
• The need for a 'superpriority' loan suggests the company's existing debt structure was problematic and that it faced challenges securing traditional financing.
• Significant board turnover, including the resignation of directors previously designated by a major shareholder, indicates a loss of control for existing equity holders and increased influence from lenders.

Risks

• Potential for further equity dilution if the delayed-draw term loans are fully utilized or if additional capital raises become necessary.
• High interest expense, even with the pay-in-kind option, could continue to strain profitability and cash flow in the long term.
• The company's underlying financial health remains precarious, as evidenced by the necessity of superpriority financing and the removal of financial covenants.
• Future liquidity challenges could arise if the delayed-draw term loans are not fully drawn or if operational improvements do not materialize as expected.
• Increased influence of new lenders on corporate governance through new board appointments and the Transformation Committee could lead to decisions prioritizing debt repayment over shareholder value.
• An event of default under the Priming Credit Agreement could trigger an event of default under the Amended Credit Agreement if the Priming Term Loan Obligations are accelerated.

Future Outlook

The company has secured new financing and restructured existing debt, providing a clearer path for operations until at least late 2026 with the amortization waiver. The establishment of a Transformation Committee suggests a focus on strategic changes and operational improvements. The availability of delayed-draw term loans provides potential future liquidity, contingent on meeting certain conditions.

Management Comments

• The company and certain subsidiaries intend to effect the transactions and enter into the agreements contemplated by the Superpriority Senior Secured Credit Agreement and Stock Subscription Agreements.
• The Board of Directors will appoint three new directors, and Alexander E. Timm, Alan Wheatley and Karoline Hilu will resign effective immediately before the closing of the Transactions.
• The Board of Directors will establish a Transformation Committee consisting of the New Directors and Jeremy W. Gelber.
• The company agrees to take all Necessary Action to cause the size of the Board to be increased to allow the Centerbridge Parties and NVX Holdings to designate for nomination to the Board as many individuals as necessary to fully exercise their rights under the Stockholders Agreement, should the New Directors not resign as required.

Industry Context

This filing reflects a company undergoing significant financial distress and restructuring, a common occurrence in industries facing intense competitive pressures or operational challenges. The necessity for 'superpriority' debt and the issuance of equity to existing lenders suggest limited access to traditional capital markets. The high interest rate and pay-in-kind (PIK) option are indicative of a high-risk lending environment. The substantial changes in corporate governance, including board composition and the formation of a Transformation Committee, are typical responses when lenders exert greater control over a struggling company to protect their investment and guide a potential turnaround.

Comparison to Industry Standards

• The interest rate of Adjusted Term SOFR + 8.00% is substantially higher than typical corporate borrowing rates for financially healthy companies, indicating a high-risk profile. For context, investment-grade corporate bonds might yield 4-6%, while high-yield (junk) bonds typically range from 7-10%. This rate places GoHealth's debt at the higher end of the distressed debt spectrum.
• The issuance of 19.99% equity to lenders as a condition for financing represents significant dilution, a measure often seen in distressed situations where traditional debt financing is unavailable or prohibitively expensive without an equity sweetener. This is a common feature in 'rescue financing' packages, unlike standard corporate loans or bond issuances.
• The waiver of amortization until December 31, 2026, and the removal of key financial covenants are concessions typically granted to companies facing severe liquidity or operational challenges, providing breathing room but also signaling underlying weakness. Healthy companies generally adhere to stricter covenants and amortization schedules.
• The extensive board changes, including the resignation of Centerbridge-appointed directors and the appointment of new directors, along with the formation of a Transformation Committee, suggest a shift in control and strategy, often driven by new or existing creditors seeking to protect their investment. This level of governance intervention is not standard for a healthy, publicly traded company.

Management Changes

Corporate Governance

Related Party Transactions

• The filing details transactions with existing lenders (Subscribers) who are also significant shareholders (Centerbridge Parties, NVX Holdings).
• The Waiver and Consent agreement was executed between GoHealth and these major shareholders/lenders, allowing the new financing and governance changes.

Stakeholder Impact

• **Shareholders:** Significant dilution (19.99%) due to the equity issuance to lenders. Existing shareholders' influence on the board is reduced due to director resignations and new appointments, although Centerbridge and NVX Holdings retain conditional rights to increase board size.
• **Lenders:** New superpriority debt position improves their security and priority in the capital structure. Existing lenders who participated in the roll-up and received equity gain a stronger overall position and potential upside from a turnaround.
• **Employees:** Not directly mentioned, but financial restructuring and the formation of a 'Transformation Committee' could imply future operational changes that might affect employees.
• **Customers/Suppliers:** Not directly mentioned, but improved financial stability (if the restructuring is successful) could ensure continued operations and service, potentially benefiting customers and suppliers.

Next Steps

• Funding of delayed-draw term loans: up to $15.0 million prior to November 1, 2025, up to $30.0 million prior to December 1, 2025, and the full $40.0 million thereafter.
• Continued service of New Directors on the Board and Transformation Committee until the earlier of the Termination Date (as defined in the Priming Credit Agreement) or when no longer required by transaction agreements.
• Company to enter into a Lenders Registration Rights Agreement with lenders receiving Shares in the Equity Issuance.
• If New Directors do not resign as required, the company will increase board size to allow Centerbridge Parties and NVX Holdings to designate additional directors.

Key Dates

Recommendation

The filing reveals a company in severe financial distress, resorting to highly dilutive and expensive 'rescue' financing. The terms of the new credit agreement (superpriority status, high PIK interest, significant equity issuance to lenders, removal of key financial covenants, and lender-driven board changes) are all strong indicators of a precarious financial position. While the financing provides short-term liquidity, it comes at a very high cost to existing equity holders and signals a last-resort measure. The company is effectively being recapitalized by its lenders, with existing shareholders bearing the brunt of the dilution and loss of control. This situation typically precedes further financial challenges or a significant decline in equity value, making it a strong sell for investors.

Keywords

GoHealth, financial restructuring, superpriority loan, equity issuance, board changes, corporate governance, debt financing, dilution, SEC filing, Schedule 13D, healthcare, insurance, Centerbridge